2025年刚开始,诺华制药就完成了大笔收购案。 2月11日,诺华宣布了对Anthos Therapeutics的收购计划。据悉,Anthos Therapeutics是一家总部位于波士顿的私人临床阶段生物制药企业,正致力于开发一款针对心房颤动患者中风及全身栓塞预防的晚期药物abelacimab。 公开信息显示,诺华将在交易完成后支付9.25亿美元的预付款,但须进行某些惯例调整,并在达到规定的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.